Erythrocyte aggregation and related parameters were observed in this study.Erythrocyte aggregation index, hematocrit and fibrin fibrinogen degradation products in-creased significantly at 5 minutes after oleic acid injection. Erythrocyte electrophoretic timein native plasma delayed obviously at 5 minutes after oleic acid injection, whereas that inPBS altered very little. The concentration of plasma calcium and erythrocyte intracellularmagnesium decreased at 5 minutes, while plasma magnesium increased. The stepwise reg-ression analysis suggested that during lung injury the parameters that have greatest effect onerythrocyte aggregation were the change of hematocrit, erythrocyte intracellular magnesiumand negative charge of erythrocyte surface.

Objective: To examine the effects of ? carotene and ? tocopherol on LDL oxidation by monocyte derived macrophages from SD rats (in DMEM medium). [WT5FZ]Methods: Macrophages were incubated with LDL in DMEM in which freshly dissoved VE (40,100,200 ?mol/L) and ?C (0.5,1.0,2.0 ?mol/L) had been added. After incubating for 24 h, the mediums were centrifuged to determine TBARS and lipofusin and dienes. [WT5FZ]Results: Supplementation of ? tocopherol significantly decreased TBARS, lipofusin and conjugated dienes production and electrophoretic mobility. Supplementation of ? carotene at 0.5 ?mol/L significantly decreased TBARS, lipofusin and conjugated dienes production and electrophoretic mobility, but other levels showed no effect. Increasing ? carotene concentration to 2.0 ?mol/L in the system increased the lipofusin production compared with control group. ? tocopherol at 200 ?mol/L and ? carotene at 0.5 ?mol/L were the most effective in all dose groups. [WT5FZ]Conclusion: Cell mediated oxidation of LDL can be regulated by antioxidants such as ? tocopherol and ? carotene.

Objective:To investigate the effect of VE and VC at different dietary levels on plasma lipid metabolism, lipid peroxidation and mRNA of scavenger receptor (SR). Methods:Male SD rats, fed purified and cholesterol enriched diet, were divided into five groups(12 rats per group). The experimental groups were fed diets with either VE(150 or 350 mg/kg diet) or VC (1 000 or 2 000 mg/kg diet) respectively. The experiment lasted 56 days. Results:Compared with control group, both VE and low dosage VC could significantly lower the concentrations of total cholesterol(TC), low density lipoprotein cholesterol(LDL C), atherogenic index (AI),Apo B and lipoperoxide, and increase the levels of high density lipoprotein cholesterol (HDL C), and inhibit the expression of SR mRNA..Conclusion:VE and VC can decrease the concentrations of serum TC and LDL C,restrain formation of Ox LDL and expression of SR mRNA.

Objective:To compare the efficacy of oral sulfate solution (OSS) and polyethylene glycol (PEG) electrolyte powder for colonoscopy bowel preparation.Methods:A total of 283 randomized patients from 9 centers in China taking OSS ( n=143) or PEG ( n=140) using two-day split bowel preparation regimen received colonoscopy and assessment. The primary index was the bowel preparation success rate [global Boston bowel preparation scale (BBPS)≥ 6 by independent assessment center]. Secondary indices included BBPS global and segmental scores, investigator satisfaction (5-point Likert scale) with the quality of bowel preparation, patient satisfaction assessed by questionnaires, and patient tolerance assessed by Sharma scale. Compliance and safety were compared between the two groups. Results:The bowel preparation success rates were 100.0% for OSS and 99.3% for PEG [adjusted difference 0.7% (95% CI: -5.3% - 6.7%), P<0.001 for non-inferiority]. The BBPS global score in OSS group was significantly higher than that in PEG group (8.1 VS 7.7, P<0.001). The segment BBPS scores were also higher in OSS group than those in PEG group for all 3 segments (right colon: 2.4 VS 2.3, P=0.002; transverse colon: 2.8 VS 2.7, P=0.018; left colon: 2.8 VS 2.7, P=0.007). Investigator Likert score in the OSS group was significantly higher than that in the PEG group (2.6 VS 2.3, P<0.001). There was no significant difference in compliance between OSS and PEG, except for the second dose (90.9% VS 82.6%, P=0.039). There was no significant difference in patient satisfaction, Sharma score or proportion of patients with tolerance-related symptoms between the two groups. Safety was comparable between the two groups, and all adverse events were mild to moderate. Conclusion:OSS has comparable efficacy with PEG, with higher BBPS scores in all segments, better investigator satisfaction, better compliance in split dose, and comparable patient tolerance and safety.